<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">7906158</journal-id>
<journal-id journal-id-type="pubmed-jr-id">7844</journal-id>
<journal-id journal-id-type="nlm-ta">Trends Pharmacol Sci</journal-id>
<journal-id journal-id-type="iso-abbrev">Trends Pharmacol. Sci.</journal-id>
<journal-title-group>
<journal-title>Trends in pharmacological sciences</journal-title>
</journal-title-group>
<issn pub-type="ppub">0165-6147</issn>
<issn pub-type="epub">1873-3735</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30905360</article-id>
<article-id pub-id-type="pmc">6482467</article-id>
<article-id pub-id-type="doi">10.1016/j.tips.2019.02.007</article-id>
<article-id pub-id-type="manuscript">NIHMS1024467</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A Coordinated Attack: Rett Syndrome Therapeutic Development</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Gogliotti</surname>
<given-names>Rocco G.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Niswender</surname>
<given-names>Colleen M.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Vanderbilt Department of Pharmacology and Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN, USA</aff>
<aff id="A2"><label>2</label>Vanderbilt Institute of Chemical Biology, Vanderbilt University, Nashville, TN, USA</aff>
<aff id="A3"><label>3</label>Vanderbilt Kennedy Center, Vanderbilt University Medical Center, Nashville, TN, USA</aff>
<author-notes>
<corresp id="CR1"><label>*</label>Correspondence: <email>Colleen.niswender@vanderbilt.edu</email> (C.M. Niswender).</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>19</day>
<month>4</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="ppub">
<month>4</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>25</day>
<month>4</month>
<year>2019</year>
</pub-date>
<volume>40</volume>
<issue>4</issue>
<fpage>233</fpage>
<lpage>236</lpage>
<!--elocation-id from pubmed: 10.1016/j.tips.2019.02.007-->
<abstract id="ABS1">
<p id="P1">Rett syndrome (RTT) is a neurodevelopmental disorder caused by mutations in the <italic>Methyl CpG binding protein 2</italic> (<italic>MeCP2</italic>) gene. This Science &amp; Society article focuses on pharmacological strategies that attack RTT treatment from multiple angles, including drug repurposing and <italic>de novo</italic> discovery efforts, and discusses the impacts of preclinical study design and translationally relevant outcome measures.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>